Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 8/20 | 0.59 |
| ▸ | MC1R | Q01726 | 8/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309720 | 0.86 | MC1R (0.63) | MC4RMC1R | |
| SCHEMBL2149320 | 0.79 | MC1R (0.51) | MC4RMC1R | |
| SCHEMBL2154187 | 0.79 | MC1R (0.52) | MC4RMC1R | |
| SCHEMBL20450442 | 0.77 | MC1R (0.79) | MC4RMC1RFNTA | |
| SCHEMBL1309721 | 0.77 | MC1R (0.79) | MC4RMC1RFNTA | |
| SCHEMBL16445574 | 0.75 | MC1R (0.61) | MC4RMC1R | |
| Trifluoroacetic Acid SCHEMBL1310190 | 0.74 | MC1R (0.48) | MC4RMC1R | |
| SCHEMBL15273352 | 0.74 | MC1R (0.48) | MC4RMC1R | |
| SCHEMBL1311359 | 0.74 | MC1R (0.47) | MC4RMC1R | |
| SCHEMBL1311899 | 0.71 | MC1R (0.47) | MC4RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010052253-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | MC4R 1479/4885MC1R 326/4885CPA1 1679/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | MC4R 873/4885MC1R 195/4885CPA1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.